Bayer, Nektar Join For Inhaled Drug | Chemical & Engineering News
Volume 85 Issue 33 | p. 23 | Concentrates
Issue Date: August 13, 2007

Bayer, Nektar Join For Inhaled Drug

Department: Business | Collection: Economy

Bayer HealthCare and Nektar Therapeutics will develop an inhalable version of the aminoglycoside antibiotic amikacin, using Nektar's drug delivery technology. The compound is in Phase II clinical trials for treating ventilated patients with hospital-acquired gram-negative pneumonias, which cause a significant number of deaths. Nektar will receive $50 million up-front and possibly another $125 million if milestones are met. Bayer will handle clinical development and manufacturing. The partners will copromote the product in the U.S. and share profits; Nektar will receive royalties on non-U.S. sales.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment